Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

Comorbidities, are common in COPD, have been associated with poor are thought to relate to systemic inflammation. To investigate relation to systemic inflammation and outcomes we recorded comorbidities well characterized cohort (ECLIPSE study) for 2164 clinically stable subjects, 337 smokers and 245 non-smokers with normal lung function. patients had a higher prevalence of osteoporosis, anxiety/panic attacks, trouble, heart attack, and heart failure, than smokers or nonsmokers. failure (Hazard Ratio [HR] 1.9, 95% Confidence Interval [CI] 1.3-2.9), heart disease (HR 1.5, 95% CI 1.1-2.0), heart disease (HR 1.5, 95% CI and diabetes (HR 1.7, 95% CI 1.2-2.4) had increased odds of mortality coexistent with COPD. Multiple comorbidities had accumulative effect on mortality. COPD and cardiovascular disease was associated with poorer life, higher MRC dyspnea scores, reduced 6MWD, higher BODE index scores. Osteoporosis, hypertension and diabetes were associated with higher MRC scores and reduced 6MWD. Higher blood concentrations of fibrinogen, IL-6 levels occurred in those with heart disease. Comorbidity is associated clinical outcomes in COPD. The comorbidities of heart disease, diabetes are associated with increased systemic inflammation